News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,182 Results
Type
Article (42252)
Company Profile (436)
Press Release (670494)
Multimedia
Podcasts (76)
Webinars (13)
Section
Business (208709)
Career Advice (2021)
Deals (36002)
Drug Delivery (104)
Drug Development (83565)
Employer Resources (173)
FDA (16419)
Job Trends (15091)
News (352738)
Policy (33068)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2642)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50930)
ALS (92)
Alzheimer's disease (1420)
Antibody-drug conjugate (ADC) (127)
Approvals (16407)
Artificial intelligence (257)
Autoimmune disease (24)
Automation (15)
Bankruptcy (371)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (105)
Biotechnology (330)
Bladder cancer (65)
Brain cancer (26)
Breast cancer (270)
Cancer (2143)
Cardiovascular disease (179)
Career advice (1687)
Career pathing (29)
CAR-T (150)
Cell therapy (426)
Cervical cancer (19)
Clinical research (67634)
Collaboration (838)
Compensation (516)
Complete response letters (24)
COVID-19 (2642)
CRISPR (42)
C-suite (235)
Cystic fibrosis (105)
Data (2083)
Decentralized trials (2)
Denatured (27)
Depression (47)
Diabetes (261)
Diagnostics (6408)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (105)
Drug shortages (26)
Duchenne muscular dystrophy (98)
Earnings (87578)
Editorial (39)
Employer branding (21)
Employer resources (147)
Events (115448)
Executive appointments (712)
FDA (17624)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (753)
Gene editing (109)
Generative AI (20)
Gene therapy (312)
GLP-1 (737)
Government (4491)
Grass and pollen (4)
Guidances (51)
Healthcare (19143)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (123)
Indications (27)
Infectious disease (2785)
Inflammatory bowel disease (140)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (92)
Interviews (311)
IPO (16776)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (36)
Layoffs (489)
Leadership (17)
Legal (7982)
Liver cancer (73)
Lung cancer (309)
Lymphoma (141)
Machine learning (5)
Management (58)
Manufacturing (290)
MASH (65)
Medical device (13495)
Medtech (13500)
Mergers & acquisitions (19737)
Metabolic disorders (691)
Multiple sclerosis (77)
NASH (19)
Neurodegenerative disease (97)
Neuropsychiatric disorders (30)
Neuroscience (1964)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2565)
Now hiring (38)
Obesity (376)
Opinion (222)
Ovarian cancer (75)
Pain (84)
Pancreatic cancer (81)
Parkinson's disease (153)
Partnered (21)
Patents (225)
Patient recruitment (100)
Peanut (47)
People (58594)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21249)
Phase II (29842)
Phase III (22072)
Pipeline (1140)
Policy (136)
Postmarket research (2601)
Preclinical (9069)
Press Release (67)
Prostate cancer (101)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (396)
Real estate (6014)
Recruiting (66)
Regulatory (22666)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (73)
Series A (134)
Series B (87)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2220)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3758)
State (2)
Stomach cancer (14)
Supply chain (66)
Tariffs (24)
The Weekly (47)
United States (22596)
Vaccines (687)
Venture capitalists (39)
Weight loss (250)
Women's health (36)
Worklife (16)
Date
Today (108)
Last 7 days (515)
Last 30 days (2548)
Last 365 days (34006)
2025 (9465)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (237)
Arkansas (14)
Asia (39169)
Australia (6524)
California (5914)
Canada (1952)
China (499)
Colorado (260)
Connecticut (275)
Delaware (137)
Europe (85581)
Florida (864)
Georgia (203)
Idaho (57)
Illinois (531)
India (25)
Indiana (304)
Iowa (10)
Japan (151)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (877)
Massachusetts (4514)
Michigan (217)
Minnesota (384)
Mississippi (2)
Missouri (79)
Montana (29)
Nebraska (25)
Nevada (60)
New Hampshire (66)
New Jersey (1693)
New Mexico (30)
New York (1673)
North Carolina (1003)
North Dakota (7)
Northern California (2565)
Ohio (197)
Oklahoma (14)
Oregon (37)
Pennsylvania (1320)
Puerto Rico (11)
Rhode Island (31)
South America (1110)
South Carolina (20)
South Dakota (1)
Southern California (2220)
Tennessee (99)
Texas (880)
Utah (174)
Virginia (140)
Washington D.C. (61)
Washington State (552)
West Virginia (3)
Wisconsin (52)
713,182 Results for "xylocor therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease
January 7, 2025
·
5 min read
Pharm Country
XyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions
XyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions.
May 2, 2024
·
6 min read
Drug Development
XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023
XyloCor Therapeutics, Inc. presented results from the Phase 2 portion of its Phase 1/2 clinical trial of its lead gene therapy candidate XC001 for refractory angina at the European Society of Cardiology Congress 2023.
August 25, 2023
·
5 min read
Press Releases
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
July 10, 2024
·
6 min read
Drug Development
Results from XyloCor Therapeutics’ Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions
Results from XyloCor Therapeutics’ Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions.
August 3, 2023
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
April 3, 2025
·
4 min read
Drug Development
XyloCor Therapeutics Reports Sustained Results in 12-Month Extension of Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina
XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today reported positive 12-month data from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) designed to assess the safety and provide preliminary evidence of efficacy of lead gene therapy candidate XC001 (encoberminogene rezmadenovec) in patients with refractory angina.
July 18, 2023
·
5 min read
Drug Development
XyloCor Advances Cardiovascular Gene Therapy Space with Positive Angina Results
XyloCor Therapeutics reported positive topline results Thursday from Phase II of the Phase I/II trial of its gene therapy for refractory angina.
January 27, 2023
·
2 min read
·
Heather McKenzie
Press Releases
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
March 26, 2025
·
4 min read
1 of 71,319
Next
